MARY CROWLEY NEWSLETTER: VOLUME 7 ISSUE 4
EFFECTS OF ALISERTIB, AN INVESTIGATIONAL AURORA A KINASE INHIBITOR ON THE QTC INTERVAL IN PATIENTS WITH ADVANCED MALIGNANCIES.
Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Lockhart AC, Goodman D, Huebner D, Mould DR, Venkatakrishnan K. Effects of Alisertib, an investigational Aurora A kinase inhibitor on the QTc interval in patients with advanced malignancies. Investigational New Drugs. 2017 Aug 18 [Epub ahead of print].
HARNESSING THE IMMUNE RESPONSE TO TARGET TUMORS
Manning L, Nemunaitis J. Harnessing the immune response to target tumors. Faculty of 1000. 2017 May 18;6:710. doi: 10.12688/f1000research.10795.1. eCollection 2017. Review.
A FIRST-IN-HUMAN, PHASE I, DOSE-ESCALATION STUDY OF TAK-117, A SELECTIVE PI3KΑ ISOFORM INHIBITOR, IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Juric D, de Bono J, LoRusso P, Nemunaitis J, Heath EI, Kwak EL, Mercade TM, Geuna E, de Miguel-Luken MJ, Patel C, Kuida K, Sankoh S, Westin E, Zohren F, Shou Y, Tabernero J. A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 2017 Sept 1;23(17):5015-5023.
SAFETY, TRAFFICKING AND ANTITUMOR ACTIVITY OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS SPECIFIC FOR TAG-72 IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, Trafficking and Antitumor Activity of Chimeric Antigen Receptor (CAR)-T Cells Specific for TAG-72 in Patients with Metastatic Colorectal Cancer. Journal for Immunotherapy of Cancer. 2017 Mar 21; 5-22. eCollection 2017.
IMMUNE CHECKPOINT INHIBITOR ELICITED COMPLETE RESPONSE IN A HEAVILY PRETREATED PATIENT WITH METASTATIC ENDOMETRIAL CARCINOMA WITH A HIGH TUMOR MUTATION BURDEN (TMB)
Barve M, Adams N, Plato L, Dupler R, Anand R, Jones J, Brown M, Stephens PJ, Shiller SM, Senzer N, Nemunaitis J. Case Report: Immune Checkpoint Inhibitor Elicited Complete Response in a Heavily Pretreated Patient with Metastatic Endometrial Carcinoma with a High Tumor Mutation Burden (TMB). Molecular Medicine. 2017 Dec 6; 1(1):005.
FUTURE DIRECTIONS FOR IMMUNOTHERAPY IN OVARIAN CANCER
Manning L, Nemunaitis J. Future Directions for Immunotherapy in Ovarian Cancer. Journal of Gynecology and Women’s Health. 2017; 2(3): 555587.
EFFECTS OF RIFAMPIN, ITRACONAZOLE AND ESOMEPRAZOLE ON THE PHARMACOKINETICS OF ALISERTIB, AN INVESTIGATIONAL AURORA A KINASE INHIBITOR IN PATIENTS WITH ADVANCED MALIGNANCIES
Zhou X, Pant S, Nemunaitis J, Lockhart AC, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargefrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational Aurora A kinase inhibitor in patients with advanced malignancies. Investigational New Drugs. 2017 Aug 30; [Epub ahead of print].
IMMUNOTHERAPY, CHECKPOINT INHIBITOR ADVANCE TO FRONTLINE NSCLC
Nemunaitis J, Senzer N. Editorial: Immunotherapy, checkpoint inhibitor advance to frontline NSCLC. Translational Cancer Research. 2017;6(Suppl 1):S141-144.